Purple Biotech To Present New CM24 Pancreatic Cancer Biomarker Data At AACR Special Conference On September 28, 2023
Portfolio Pulse from Benzinga Newsdesk
Purple Biotech Ltd. (NASDAQ/TASE: PPBT) will present new biomarker data for its Phase 1 study of CM24 in combination with Nivolumab in patients with advanced pancreatic cancer at the AACR Special Conference on September 28, 2023. The data will be shared via a press release after the poster presentation.
September 21, 2023 | 12:21 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Purple Biotech's presentation of new biomarker data could potentially impact the company's stock positively if the data is promising.
The presentation of new biomarker data is a significant event for Purple Biotech. If the data shows positive results, it could increase investor confidence in the company's research and development capabilities, potentially leading to a rise in the company's stock price.
CONFIDENCE 70
IMPORTANCE 80
RELEVANCE 100